Back to top

Morgan Stanley Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)

Morgan Stanley analyst Sean Laaman maintained a Buy rating on Jazz Pharmaceuticals yesterday and set a price target of $283.00. The company’s share...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Jazz Pharmaceuticals PLC (JAZZ)